Spyre Therapeutics (SYRE) Tax Provisions (2021 - 2025)
Spyre Therapeutics' (SYRE) quarterly Tax Provisions came in at -$15000.0 in Q1 2025, down 146.88% YoY from $32000.0 in Q1 2024, and down 1600.0% on a QoQ basis from $1000.0 in Q4 2024.
Powered by 
Analysis
Spyre Therapeutics (SYRE) Tax Provisions (2021 - 2025) Analysis & Trends
Spyre Therapeutics (SYRE) has 5 years of Tax Provisions data on file, last reported at -$15000.0 in Q1 2025.
- Quarterly Tax Provisions fell 146.88% year-over-year to -$15000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$15000.0 (down 129.41% YoY) and the FY2025 annual result came in at -$15000.0, down 129.41% from the prior year.
- Tax Provisions eased to -$15000.0 in Q1 2025, from $1000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $92000.0 in Q2 2021 to a low of -$209000.0 in Q3 2022.
- A 5-year average of -$846.15 and a median of $9000.0 in 2022 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions plunged 903.85% — and 2024, when it soared 500.0%.
- Tracing SYRE's Tax Provisions over 5 years: stood at $23000.0 in 2021, then soared by 65.22% to $38000.0 in 2022, then plunged by 92.11% to $3000.0 in 2023, then slumped by 66.67% to $1000.0 in 2024, then sank by 1600.0% to -$15000.0 in 2025.
- The last three Tax Provisions figures came in at -$15000.0 (Q1 2025), $1000.0 (Q4 2024), and $18000.0 (Q3 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Spyre Therapeutics | 7.40 Bn | 7.40 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -15,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | -36,000.00 |
| Dec 31, 2022 | 38,000.00 |
| Sep 30, 2022 | -209,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Dec 31, 2021 | 23,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Jun 30, 2021 | 92,000.00 |